Flashforward EMDR Treatment for Patients With an ICD
eFFective
The Effectiveness of Flashforward EMDR Treatment for Patients With an ICD
1 other identifier
interventional
33
0 countries
N/A
Brief Summary
The goal of this randomized controlled trial is to test whether flashforward (FF) EMDR alone is effective in reducing anxiety symptoms in patients with an implantable cardioverter defibrillator (ICD). Participants will fill out several questionnaires to asses their level of anxiety, depression symptoms and quality of life before, during and after treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 8, 2023
CompletedFirst Posted
Study publicly available on registry
December 18, 2023
CompletedStudy Start
First participant enrolled
February 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedDecember 19, 2023
December 1, 2023
1 year
December 8, 2023
December 18, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cardiac Anxiety Questionnaire (CAQ)
Self-report questionnaire to asses heart focussed anxiety
Baseline (Before treatment T0), after the first treatment session T1(for wait list after 2 weeks), and after the second treatment session T2 (for wait list after 4 weeks)
Secondary Outcomes (4)
PTSD Check-List (PCL-5)
Baseline (Before treatment T0) and after the second treatment session T2 (for wait list after 4 weeks)
General Anxiety Questionnaire (GAD-7)
Baseline (Before treatment T0) and after the second treatment session T2 (for wait list after 4 weeks)
Patient Health Questionnaire (PHQ-9)
Baseline (Before treatment T0) and after the second treatment session T2 (for wait list after 4 weeks)
EuroQol (EQ5D-5L)
Baseline (Before treatment T0) and after the second treatment session T2 (for wait list after 4 weeks)
Other Outcomes (1)
Life Events Checklist (LEC-5)
Baseline (Before treatment T0)
Study Arms (3)
FF EMDR
EXPERIMENTALSubjects in this group will receive two EMDR treatment sessions following the flashforward protocol.
FB EMDR
ACTIVE COMPARATORSubjects in this group will receive two EMDR treatment sessions following the flashback protocol.
Control group
NO INTERVENTIONSubjects in this group will not receive any treatment until the wait list period (4 weeks) is over
Interventions
The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
Eligibility Criteria
You may qualify if:
- subjects have an ICD;
- subjects have clinical anxiety symptoms related to their ICD.
You may not qualify if:
- insufficient knowledge on Dutch or English language;
- severe psychiatric disorders that warrant (other) psychiatric first, such as suicidality or psychotic disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- The study will have an open label, since the care provider (the psychologist) needs to know which procedure to follow and the participants will understand in which group they are once the therapy start.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
December 8, 2023
First Posted
December 18, 2023
Study Start
February 1, 2024
Primary Completion
February 1, 2025
Study Completion
July 1, 2025
Last Updated
December 19, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share
Data will be available, anonymized, to other researchers, upon reasonable request.